Christopher Yea is CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc. (KALV). They have made 42 open-market trades across 1 company since 2019, most recently 2026-05-27.
CIK 0001691102
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 42 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KALV | 229,918 | $6.2M |
Shares reported on the most recent Form 4, priced at the 2026-05-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KALV | SELL | 2026-05-27 | 2026-05-29 | $26.78 | $905K | +0.2% | N/A | N/A |
| KALV | SELL | 2026-05-26 | 2026-05-27 | $26.78 | $53K | +0.7% | N/A | N/A |
| KALV | SELL | 2026-05-22 | 2026-05-26 | $26.78 | $63K | +0.7% | N/A | N/A |
| KALV | SELL | 2026-05-18 | 2026-05-19 | $26.76 | $30K | +0.7% | N/A | N/A |
| KALV | SELL | 2026-02-23 | 2026-02-24 | $15.57 | $68K | +2.8% | +20.0% | +69.8% |
| KALV | SELL | 2026-02-18 | 2026-02-19 | $15.00 | $17K | +0.0% | +6.3% | +71.7% |
| KALV | SELL | 2025-11-24 | 2025-11-26 | $13.45 | $117K | +14.5% | +7.5% | +11.8% |
| KALV | SELL | 2025-11-18 | 2025-11-19 | $14.48 | $39K | -2.2% | +10.1% | +8.4% |
| KALV | SELL | 2025-08-25 | 2025-08-26 | $13.42 | $26K | +21.2% | -8.2% | +1.4% |
| KALV | SELL | 2025-08-22 | 2025-08-25 | $13.22 | $31K | +22.8% | +0.2% | +3.6% |
| KALV | SELL | 2025-08-18 | 2025-08-19 | $13.19 | $35K | +5.1% | +8.4% | +16.0% |
| KALV | SELL | 2025-07-09 | 2025-07-10 | $15.69 | $949K | +6.3% | -15.9% | -22.8% |
| KALV | SELL | 2025-05-23 | 2025-05-27 | $11.31 | $22K | +28.0% | +2.5% | +15.8% |
| KALV | SELL | 2025-05-22 | 2025-05-23 | $11.88 | $28K | +19.0% | +2.8% | +11.7% |
| KALV | SELL | 2025-05-19 | 2025-05-20 | $11.84 | $31K | +7.0% | +0.7% | +10.5% |
| KALV | SELL | 2025-02-24 | 2025-02-25 | $10.02 | $19K | +10.4% | +14.3% | +3.9% |
| KALV | SELL | 2025-02-18 | 2025-02-19 | $9.82 | $26K | +1.5% | +11.0% | +14.3% |
| KALV | SELL | 2024-11-26 | 2024-11-27 | $9.87 | $19K | -5.7% | -14.8% | +7.6% |
| KALV | SELL | 2024-11-18 | 2024-11-19 | $9.26 | $133K | +14.1% | -10.1% | +8.7% |
| KALV | SELL | 2024-08-23 | 2024-08-26 | $12.40 | $24K | -5.4% | -27.5% | -22.8% |
| KALV | SELL | 2024-08-19 | 2024-08-21 | $12.01 | $171K | -0.9% | -15.9% | -27.5% |
| KALV | SELL | 2024-05-20 | 2024-05-21 | $11.76 | $273K | +5.6% | -2.3% | +6.7% |
| KALV | SELL | 2024-02-20 | 2024-02-21 | $14.11 | $340K | +7.0% | -9.6% | -11.4% |
| KALV | SELL | 2024-02-14 | 2024-02-16 | $15.01 | $1.2M | -6.5% | -17.9% | -17.3% |
| KALV | SELL | 2023-11-20 | 2023-11-21 | $8.23 | $117K | +11.4% | +41.2% | +72.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.